CClinicalTrials.gg
CompletedNCT00642330Updated Mar 25, 2008

Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants

A Phase 4 interventional study of oral ibuprofen and intravenous ibuprofen in Patent Ductus Arteriosus, sponsored by Hopital La Rabta. Completed at 1 site in Tunisia. Open to participants aged 48 Hours to 96 Hours. Per ClinicalTrials.gov, last updated 2008-03-25.

Sponsored by Hopital La Rabta · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
48 Hours to 96 Hours
Sex
All
01

Study summary

it is a prospective randomized simple-blinded pilot trial with the principal aim to compare efficacy and tolerance between oral ibuprofen and intravenous ibuprofen in early curative closure of PDA in very low birth weight infants. The likelihood of ductal closure with only one or two doses of treatment is a secondary objective.

Read the detailed description

We calculated that a study group of 62 patients would be necessary for the study to be able to detect a difference of at least 25 percentage points in the closure rate between the oral ibuprofen and intravenous ibuprofen groups, assuming a closure rate of 65 percent with intravenous ibuprofen, with a p value of 0, 05 and a power of 80 percent.Patients (gestational age, 25 to 32 weeks) with echocardiographically confirmed patent ductus arteriosus and respiratory distress will randomly be assigned to receive one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of either intravenous ibuprofen (group I, n = 32) or oral ibuprofen (group O, n = 32), starting on the third day of life. The rate of ductal closure, side effects, complications, and the patients' clinical course will be recorded.

02

Conditions studied

  • Patent Ductus Arteriosus

Keywords

  • patent
  • ductus
  • arteriosus
  • ibuprofen
  • premature
  • infant
03

In context

Ductus Arteriosus, Patent

144 studies on the registry are indexed under Ductus Arteriosus, Patent; 17 are open to participants now.

This study's enrollment of 62 is below the median of 80 across 81 interventional studies indexed under Ductus Arteriosus, Patent.

Browse Ductus Arteriosus, Patent studies →

Lead sponsor

Hopital La Rabta is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
48 Hours to 96 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • a gestational age \< 32 weeks
  • a birth weight \< 1500g
  • a postnatal age between 48 and 96 hours, a respiratory distress requiring more than 25 % of oxygen supplementation
  • an echocardiographic evidence of left to right significant shunting PDA

Exclusion criteria

Exclusion Criteria:

  • a right-to-left shunting
  • major congenital anomalies
  • IVH grade 3-4
  • a tendency to bleed (defined by the presence of blood in the endotracheal aspirate, gastric aspirate, stools or urines and / or oozing from puncture sites)
  • a serum creatinine level >140µmol/l, a serum urea nitrogen > 14 µmol/l and a platelet count \< 60000/mm3.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    I

    Drug: intravenous ibuprofen

  • Active comparator
    O

    Drug: oral ibuprofen

Interventions

  • Drugoral ibuprofen

    one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.

  • Drugintravenous ibuprofen

    one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.

06

What researchers measure

Primary outcomes

  1. rate of ductal closure

Secondary outcomes

  1. rate of side effects

07

Study locations

1 site
  • Maternity and Neonatal Center
    Tunis, 1007, Tunisia
08

References and documents

Publications

  • Cherif A, Jabnoun S, Khrouf N. Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants. Am J Perinatol. 2007 Jun;24(6):339-45. doi: 10.1055/s-2007-981853. Epub 2007 Jun 12. PubMed 17564958 ↗
  • Cherif A, Khrouf N, Jabnoun S, Mokrani C, Amara MB, Guellouze N, Kacem S. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics. 2008 Dec;122(6):e1256-61. doi: 10.1542/peds.2008-1780. PubMed 19047225 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00642330
Lead sponsor
Hopital La Rabta
Collaborators
maternity and neonatal center
First posted
Mar 25, 2008
Start date
Jan 2007
Primary completion
Mar 2007
Completion
Dec 2007
Last update
Mar 25, 2008

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion